TCP1 alpha/CCTA antibody (full length)

Catalog No. ABIN7879122

The Mouse Monoclonal anti-TCP1 alpha/CCTA antibody is suitable to detect TCP1 alpha/CCTA in samples from Human. It has been validated for IHC (p).

Quick Overview for TCP1 alpha/CCTA antibody (full length) (ABIN7879122)

Target: TCP1 alpha/CCTA (TCP1) (T-Complex 1 (TCP1))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This TCP1 alpha/CCTA antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: TP63-2427

Product Details anti-TCP1 alpha/CCTA Antibody

Binding Specificity: full length

Purpose: p63 Antibody

Purification: Protein G affinity chromatography

Immunogen: Full length human recombinant protein was used as the immunogen for the p63 antibody.

Isotype: IgG2b, kappa

Application Details

Application Notes: Optimal dilution of the p63 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store the p63 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Target Details for TCP1 alpha/CCTA

Target: TCP1 alpha/CCTA (TCP1) (T-Complex 1 (TCP1))

Alternative Name: p63

Background: P63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands, however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90 % . Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80 %. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

UniProt: Q9H3D4